CPT-11 (Irinotecan) in the treatment of colorectal cancer
- 1 July 1995
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 31 (7-8), 1283-1287
- https://doi.org/10.1016/0959-8049(95)00212-2
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical TrialsJNCI Journal of the National Cancer Institute, 1994
- Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1994
- DNA Topoisomerases: Essential Enzymes and Lethal TargetsAnnual Review of Pharmacology and Toxicology, 1994
- Topoisomerase I inhibitors: topotecan and irenotecanCancer Treatment Reviews, 1994
- Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.BMJ, 1993
- The chemotherapy of colon cancer can no longer be ignoredEuropean Journal Of Cancer, 1993
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1992
- Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.Journal of Clinical Oncology, 1992
- Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma assessment of activity and toxicityCancer, 1990
- Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.Journal of Clinical Oncology, 1990